Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

The multiple roles of PTEN in tumor suppression.

Di Cristofano A, Pandolfi PP.

Cell. 2000 Feb 18;100(4):387-90. Review. No abstract available.

2.

Stem cells. PTEN--coupling tumor suppression to stem cells?

Penninger JM, Woodgett J.

Science. 2001 Dec 7;294(5549):2116-8. No abstract available.

PMID:
11739945
3.

Gatekeeper for endometrium: the PTEN tumor suppressor gene.

Ali IU.

J Natl Cancer Inst. 2000 Jun 7;92(11):861-3. No abstract available.

4.

PTEN: life as a tumor suppressor.

Simpson L, Parsons R.

Exp Cell Res. 2001 Mar 10;264(1):29-41. Review.

PMID:
11237521
5.

The complexity of PTEN: mutation, marker and potential target for therapeutic intervention.

Steelman LS, Bertrand FE, McCubrey JA.

Expert Opin Ther Targets. 2004 Dec;8(6):537-50. Review.

PMID:
15584861
6.

[PTEN: a tumor suppressor with original properties].

Roux P.

Bull Cancer. 1999 Jun;86(6):522-5. French.

PMID:
10417424
7.

[Genes & cancer. Card no. 28: PTEN (MMAC, TEP-1) (phosphatase and tensin homolog deleted on chromosome 10)].

Soussi T.

Bull Cancer. 1999 Sep;86(9):715-6. French. No abstract available.

PMID:
10576807
8.

[PTEN tumor suppressor: functions as a lipid phosphatase].

Maehama T, Dixon JE.

Tanpakushitsu Kakusan Koso. 2000 Oct;45(14):2405-14. Review. Japanese. No abstract available.

PMID:
11051842
9.

The tumour suppressor PTEN: involvement of a tumour suppressor candidate protein in PTEN turnover.

Maehama T, Okahara F, Kanaho Y.

Biochem Soc Trans. 2004 Apr;32(Pt 2):343-7. Review.

PMID:
15046605
10.

PTEN, a unique tumor suppressor gene.

Dahia PL.

Endocr Relat Cancer. 2000 Jun;7(2):115-29. Review.

11.

PTEN and p53: who will get the upper hand?

Trotman LC, Pandolfi PP.

Cancer Cell. 2003 Feb;3(2):97-9. No abstract available.

12.

The role of genetic abnormalities of PTEN and the phosphatidylinositol 3-kinase pathway in breast and ovarian tumorigenesis, prognosis, and therapy.

Mills GB, Lu Y, Fang X, Wang H, Eder A, Mao M, Swaby R, Cheng KW, Stokoe D, Siminovitch K, Jaffe R, Gray J.

Semin Oncol. 2001 Oct;28(5 Suppl 16):125-41. Review.

PMID:
11706404
13.

PTEN regulatory functions in tumor suppression and cell biology.

Chu EC, Tarnawski AS.

Med Sci Monit. 2004 Oct;10(10):RA235-41. Epub 2004 Sep 23. Review.

PMID:
15448614
14.

Structural assets of a tumor suppressor.

Tonks NK, Myers MP.

Science. 1999 Dec 10;286(5447):2096-7. No abstract available.

PMID:
10617421
15.

The biology and clinical relevance of the PTEN tumor suppressor pathway.

Sansal I, Sellers WR.

J Clin Oncol. 2004 Jul 15;22(14):2954-63. Review.

PMID:
15254063
16.

Cell cycle arrest by the PTEN tumor suppressor is target cell specific and may require protein phosphatase activity.

Hlobilkova A, Guldberg P, Thullberg M, Zeuthen J, Lukas J, Bartek J.

Exp Cell Res. 2000 May 1;256(2):571-7.

PMID:
10772829
17.

PTEN polymorphism (IVS4) is not associated with risk of prostate cancer.

George DJ, Shepard TF, Ma J, Giovannucci E, Kantoff PW, Stampfer MJ.

Cancer Epidemiol Biomarkers Prev. 2001 Apr;10(4):411-2. No abstract available.

18.

PTEN.

Stokoe D.

Curr Biol. 2001 Jul 10;11(13):R502. No abstract available.

20.

PTEN and cancer.

Parsons R, Simpson L.

Methods Mol Biol. 2003;222:147-66. Review. No abstract available.

PMID:
12710685
Items per page

Supplemental Content

Write to the Help Desk